Immuneering CPO acquires shares via ESPP

Immuneering Corp’s Chief People Officer, Leah R. Neufeld, acquired additional company stock through an employee plan.

Rhea-AI Filing Summary

Immuneering Corp’s Chief People Officer, Leah R. Neufeld, acquired additional company stock through an employee plan. She obtained 3,628 shares of Class A Common Stock on the ESPP Purchase Date of March 13, 2026 at $4.2925 per share, under the 2021 Employee Stock Purchase Plan for the offering period from September 16, 2025 through March 15, 2026. The plan price was set at not less than 85% of the fair market value on the purchase date. Following this routine, compensation-related acquisition, Neufeld directly holds 29,598 shares, and the transaction is exempt under Rule 16b-3(c).

Insider Trade Summary

Grant/Award: 3,628 shares

Grant/Award 1 txn

Insider Neufeld Leah R

Role CHIEF PEOPLE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	3,628	$4.2925	$16K

Holdings After Transaction: Class A Common Stock — 29,598 shares (Direct)

Footnotes (3)

1. F1. The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 16, 2025 through March 15, 2026. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.
2. F2. The relevant Offering Period (as defined in the ESPP) ended on March 15, 2026. The shares were acquired on the Purchase Date (as defined in the ESPP) of March 13, 2026.
3. F3. In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of the relevant Offering Period.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immuneering Corp (IMRX) insider Leah R. Neufeld report on this Form 4?

Leah R. Neufeld, Immuneering’s Chief People Officer, reported acquiring 3,628 shares of Class A Common Stock. The shares were purchased through the company’s 2021 Employee Stock Purchase Plan for an offering period ending March 15, 2026, reflecting routine participation in an employee benefit program.

How many Immuneering Corp (IMRX) shares did Leah R. Neufeld acquire and at what price?

Neufeld acquired 3,628 shares of Immuneering Class A Common Stock at $4.2925 per share. The purchase occurred on March 13, 2026 under the Employee Stock Purchase Plan, which set the price at not less than 85% of the fair market value on the purchase date.

How many Immuneering Corp (IMRX) shares does Leah R. Neufeld own after this transaction?

After this acquisition, Neufeld directly owns 29,598 shares of Immuneering Class A Common Stock. This total reflects her position following the March 13, 2026 Employee Stock Purchase Plan purchase and shows her continued equity stake as Chief People Officer in the company.

What is the Immuneering Corp (IMRX) Employee Stock Purchase Plan mentioned in the filing?

The Immuneering Corporation 2021 Employee Stock Purchase Plan allows eligible employees to buy Class A Common Stock at a discount. In this case, shares were bought for an offering period running September 16, 2025 to March 15, 2026, with pricing tied to fair market value on the purchase date.

What discount did Leah R. Neufeld receive on Immuneering Corp (IMRX) shares under the ESPP?

Under the Employee Stock Purchase Plan, Neufeld’s shares were purchased at a price not less than 85% of the fair market value on the March 13, 2026 purchase date. This reflects a standard ESPP discount structure rather than a negotiated or discretionary transaction.

Is Leah R. Neufeld’s Immuneering Corp (IMRX) transaction considered exempt under SEC rules?

Yes. The filing states the acquisition under the Employee Stock Purchase Plan is exempt pursuant to Rule 16b-3(c) under the Securities Exchange Act of 1934. This rule generally covers certain employee benefit plan-related transactions by officers and directors, treating them as exempt from short-swing profit rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 04:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Neufeld Leah R

(Last) (First) (Middle)

245 MAIN STREET

SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF PEOPLE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock(1)	03/13/2026(2)		A		3,628	A	$4.2925(3)	29,598	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 16, 2025 through March 15, 2026. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.

2. The relevant Offering Period (as defined in the ESPP) ended on March 15, 2026. The shares were acquired on the Purchase Date (as defined in the ESPP) of March 13, 2026.

3. In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of the relevant Offering Period.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Leah R. Neufeld	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.